Intramuscular atenolol and levetiracetam reduce mortality in a rat model of paraoxon-induced status epilepticus
© 2020 New York Academy of Sciences..
Organophosphorus (OP) compounds are chemical threat agents and are irreversible inhibitors of the enzyme acetylcholinesterase that lead to a hypercholinergic response that could include status epilepticus (SE). SE particularly targets the heart and brain and despite existing therapies, it is still associated with significant mortality and morbidity. Here, we investigated the effect of intramuscular (i.m.) adjunct therapy consisting of atenolol (AT) and levetiracetam (LV) when administered after paraoxon (POX)-induced SE. The combination therapy was administered twice daily for 2, 7, or 14 days. POX exposure in rats produced rapid SE onset that was treated with atropine, pralidoxime chloride, and midazolam. Here, AT + LV therapy produced significant reductions in POX SE mortality assessed at 30 days post-SE. AT + LV therapy exhibited muscle pathology inflammation scores that were not significantly different from saline-treated controls. Pharmacokinetic analyses revealed that the i.m. route achieved faster and stabler plasma therapeutic levels for both AT and LV under OP SE conditions compared with oral administrations. Our data provide evidence of the safety and efficacy of i.m. AT + LV therapy for reducing mortality following POX SE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1480 |
|---|---|
| Enthalten in: |
Annals of the New York Academy of Sciences - 1480(2020), 1 vom: 22. Nov., Seite 219-232 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deshpande, Laxmikant S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
44YRR34555 |
|---|
| Anmerkungen: |
Date Completed 30.12.2020 Date Revised 02.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/nyas.14500 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315327707 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315327707 | ||
| 003 | DE-627 | ||
| 005 | 20231225154657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/nyas.14500 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315327707 | ||
| 035 | |a (NLM)32961584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deshpande, Laxmikant S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intramuscular atenolol and levetiracetam reduce mortality in a rat model of paraoxon-induced status epilepticus |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2020 | ||
| 500 | |a Date Revised 02.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 New York Academy of Sciences. | ||
| 520 | |a Organophosphorus (OP) compounds are chemical threat agents and are irreversible inhibitors of the enzyme acetylcholinesterase that lead to a hypercholinergic response that could include status epilepticus (SE). SE particularly targets the heart and brain and despite existing therapies, it is still associated with significant mortality and morbidity. Here, we investigated the effect of intramuscular (i.m.) adjunct therapy consisting of atenolol (AT) and levetiracetam (LV) when administered after paraoxon (POX)-induced SE. The combination therapy was administered twice daily for 2, 7, or 14 days. POX exposure in rats produced rapid SE onset that was treated with atropine, pralidoxime chloride, and midazolam. Here, AT + LV therapy produced significant reductions in POX SE mortality assessed at 30 days post-SE. AT + LV therapy exhibited muscle pathology inflammation scores that were not significantly different from saline-treated controls. Pharmacokinetic analyses revealed that the i.m. route achieved faster and stabler plasma therapeutic levels for both AT and LV under OP SE conditions compared with oral administrations. Our data provide evidence of the safety and efficacy of i.m. AT + LV therapy for reducing mortality following POX SE | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a beta-blocker | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a paraoxon | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a status epilepticus | |
| 650 | 7 | |a Levetiracetam |2 NLM | |
| 650 | 7 | |a 44YRR34555 |2 NLM | |
| 650 | 7 | |a Atenolol |2 NLM | |
| 650 | 7 | |a 50VV3VW0TI |2 NLM | |
| 650 | 7 | |a Paraoxon |2 NLM | |
| 650 | 7 | |a Q9CX8P80JW |2 NLM | |
| 700 | 1 | |a Blair, Robert E |e verfasserin |4 aut | |
| 700 | 1 | |a Halquist, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Kosmider, Leon |e verfasserin |4 aut | |
| 700 | 1 | |a DeLorenzo, Robert J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the New York Academy of Sciences |d 1945 |g 1480(2020), 1 vom: 22. Nov., Seite 219-232 |w (DE-627)NLM000012823 |x 1749-6632 |7 nnns |
| 773 | 1 | 8 | |g volume:1480 |g year:2020 |g number:1 |g day:22 |g month:11 |g pages:219-232 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/nyas.14500 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1480 |j 2020 |e 1 |b 22 |c 11 |h 219-232 | ||